TY - JOUR
AU - H. Danysh
AU - C. Johannes
AU - D. Beachler
AU - J. Layton
AU - R. Ziemiecki
AU - A. Arana
AU - J. Dinh
AU - L. Li
AU - B. Calingaert
AU - M. Pladevall-Vila
AU - P. Hunt
AU - H. Chen
AU - C. Karlsson
AU - K. Johnsson
AU - A. Gilsenan
AD - Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, 307 Waverley Oaks Road, Suite 101, Waltham, MA, 02452-8413, USA. hdanysh@rti.org.
Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, 307 Waverley Oaks Road, Suite 101, Waltham, MA, 02452-8413, USA.
Department of Safety and Epidemiology, HealthCore, Inc., Wilmington, DE, USA.
Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, Research Triangle Park, NC, USA.
Department of Biostatistics, RTI Health Solutions, Research Triangle Park, NC, USA.
Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, Barcelona, Spain.
Department of Research Operations, HealthCore, Inc., Wilmington, DE, USA.
The Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, MI, USA.
BioPharmaceuticals Business Unit, AstraZeneca, Gaithersburg, MD, USA.
BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
AN - 36583828
BT - Drug Saf
DO - 10.1007/s40264-022-01262-4
DP - NLM
ET - 2022/12/31
LA - eng
N1 - 1179-1942
Danysh, Heather E
Orcid: 0000-0003-3014-7508
Johannes, Catherine B
Orcid: 0000-0002-0586-9886
Beachler, Daniel C
Orcid: 0000-0003-2788-3061
Layton, J Bradley
Orcid: 0000-0003-0994-5820
Ziemiecki, Ryan
Orcid: 0000-0002-1774-7034
Arana, Alejandro
Orcid: 0000-0002-1593-3124
Dinh, Jade
Orcid: 0000-0003-0386-2776
Li, Ling
Calingaert, Brian
Orcid: 0000-0001-8177-6326
Pladevall-Vila, Manel
Orcid: 0000-0002-9359-6055
Hunt, Phillip R
Orcid: 0000-0002-9559-175x
Chen, Hungta
Karlsson, Cecilia
Orcid: 0000-0002-4299-8775
Johnsson, Kristina
Gilsenan, Alicia
Orcid: 0000-0002-9266-1417
Journal Article
New Zealand
Drug Saf. 2022 Dec 30. doi: 10.1007/s40264-022-01262-4.
PY - 2022
SN - 0114-5916
T2 - Drug Saf
TI - Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting
ER -